Literature DB >> 6462102

Influence of azathioprine (imuran) on in vitro immune function in multiple sclerosis.

J J Oger, J P Antel, H H Kuo, B G Arnason.   

Abstract

In vitro immune function was assessed in patients with multiple sclerosis (MS) who were receiving Imuran therapy, in untreated MS patients, and in controls. In untreated stable MS patients, concanavalin A (Con A)-driven mitogenic reactivity (T effector function) and Con A-induced suppressor activity were modestly reduced compared to controls; pokeweed mitogen-induced immunoglobulin G (IgG) secretion was increased. Untreated patients with active MS demonstrated high levels of IgG secretion and marked decreases in suppressor activity. In Imuran-treated patients, Con A mitogenic responses and suppressor activity were comparable to those observed in untreated stable patients, and IgG secretion was reduced. The results in the treated patients likely reflect a direct effect of Imuran on B cell function rather than an indirect effect mediated via suppressor cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6462102     DOI: 10.1002/ana.410110211

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

1.  A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results.

Authors:  D A Compston; N M Milligan; P J Hughes; J Gibbs; V McBroom; B P Morgan; A K Campbell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-05       Impact factor: 10.154

2.  Peripheral blood lymphocyte phenotype and function in multiple sclerosis.

Authors:  P J Hughes; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

3.  The influence of disease activity on the number of blood cells of multiple sclerosis patients.

Authors:  U Patzold; U Wurster; K Mardt; M Schiemann
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

4.  Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice.

Authors:  R D Dix; R R McKendall; J R Baringer
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

Review 5.  What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Authors:  Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

6.  Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results.

Authors:  C Milanese; L La Mantia; A Salmaggi; A Campi; C Bortolami; L Tajoli; A Nespolo; F Corridori
Journal:  Ital J Neurol Sci       Date:  1988-02

7.  Reduction of immunoglobulin G secretion in vitro following long term lymphoblastoid interferon (Wellferon) treatment in multiple sclerosis patients.

Authors:  M R O'Gorman; J Oger; L F Kastrukoff
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

8.  Suppressor and cytolytic cell function in multiple sclerosis. Effects of cyclosporine A and interleukin 2.

Authors:  M B Bania; J P Antel; A T Reder; M K Nicholas; B G Arnason
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.